Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Targeting β1-integrin inhibits vascular leakage in endotoxemia.

Hakanpaa L, Kiss EA, Jacquemet G, Miinalainen I, Lerche M, Guzmán C, Mervaala E, Eklund L, Ivaska J, Saharinen P.

Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6467-E6476. doi: 10.1073/pnas.1722317115. Epub 2018 Jun 25.

2.

Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation.

Pekkonen P, Alve S, Balistreri G, Gramolelli S, Tatti-Bugaeva O, Paatero I, Niiranen O, Tuohinto K, Perälä N, Taiwo A, Zinovkina N, Repo P, Icay K, Ivaska J, Saharinen P, Hautaniemi S, Lehti K, Ojala PM.

Elife. 2018 May 1;7. pii: e32490. doi: 10.7554/eLife.32490.

3.

SnapShot: Angiopoietins and Their Functions.

Saharinen P, Leppänen VM, Alitalo K.

Cell. 2017 Oct 19;171(3):724-724.e1. doi: 10.1016/j.cell.2017.10.009.

4.

Therapeutic targeting of the angiopoietin-TIE pathway.

Saharinen P, Eklund L, Alitalo K.

Nat Rev Drug Discov. 2017 Sep;16(9):635-661. doi: 10.1038/nrd.2016.278. Epub 2017 May 19. Review.

PMID:
28529319
5.

Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.

Leppänen VM, Saharinen P, Alitalo K.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381. doi: 10.1073/pnas.1616166114. Epub 2017 Apr 10.

6.

Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems.

Eklund L, Kangas J, Saharinen P.

Clin Sci (Lond). 2017 Jan 1;131(1):87-103. Review.

7.

Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer.

Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu-Lehtinen PI.

Clin Genitourin Cancer. 2017 Feb;15(1):e15-e24. doi: 10.1016/j.clgc.2016.07.008. Epub 2016 Jul 21.

PMID:
27554585
8.

Tie1 controls angiopoietin function in vascular remodeling and inflammation.

Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D'Amico G, Sipilä TJ, Lohela M, Strandin T, Vaheri A, Ylä-Herttuala S, Koh GY, McDonald DM, Alitalo K, Saharinen P.

J Clin Invest. 2016 Sep 1;126(9):3495-510. doi: 10.1172/JCI84923. Epub 2016 Aug 22.

9.

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation.

Kim M, Allen B, Korhonen EA, Nitschké M, Yang HW, Baluk P, Saharinen P, Alitalo K, Daly C, Thurston G, McDonald DM.

J Clin Invest. 2016 Sep 1;126(9):3511-25. doi: 10.1172/JCI84871. Epub 2016 Aug 22.

10.

Critical requirement of VEGF-C in transition to fetal erythropoiesis.

Fang S, Nurmi H, Heinolainen K, Chen S, Salminen E, Saharinen P, Mikkola HK, Alitalo K.

Blood. 2016 Aug 4;128(5):710-20. doi: 10.1182/blood-2015-12-687970. Epub 2016 Jun 24.

11.

Simvastatin pretreatment reduces caspase-9 and RIPK1 protein activity in rat cardiac allograft ischemia-reperfusion.

Tuuminen R, Holmström E, Raissadati A, Saharinen P, Rouvinen E, Krebs R, Lemström KB.

Transpl Immunol. 2016 Jul;37:40-45. doi: 10.1016/j.trim.2016.05.001. Epub 2016 May 4.

PMID:
27155462
12.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

13.

VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption.

Nurmi H, Saharinen P, Zarkada G, Zheng W, Robciuc MR, Alitalo K.

EMBO Mol Med. 2015 Nov;7(11):1418-25. doi: 10.15252/emmm.201505731.

14.

Blocking integrin inactivation as an anti-angiogenic therapy.

Saharinen P, Ivaska J.

EMBO J. 2015 May 12;34(10):1293-5. doi: 10.15252/embj.201591504. Epub 2015 Mar 31. No abstract available.

15.

Endothelial destabilization by angiopoietin-2 via integrin β1 activation.

Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P.

Nat Commun. 2015 Jan 30;6:5962. doi: 10.1038/ncomms6962.

16.

The sinus venosus contributes to coronary vasculature through VEGFC-stimulated angiogenesis.

Chen HI, Sharma B, Akerberg BN, Numi HJ, Kivelä R, Saharinen P, Aghajanian H, McKay AS, Bogard PE, Chang AH, Jacobs AH, Epstein JA, Stankunas K, Alitalo K, Red-Horse K.

Development. 2014 Dec;141(23):4500-12. doi: 10.1242/dev.113639. Epub 2014 Nov 5.

17.

VEGF-C and aortic cardiomyocytes guide coronary artery stem development.

Chen HI, Poduri A, Numi H, Kivela R, Saharinen P, McKay AS, Raftrey B, Churko J, Tian X, Zhou B, Wu JC, Alitalo K, Red-Horse K.

J Clin Invest. 2014 Nov;124(11):4899-914. doi: 10.1172/JCI77483. Epub 2014 Oct 1.

18.

The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.

Aspelund A, Tammela T, Antila S, Nurmi H, Leppänen VM, Zarkada G, Stanczuk L, Francois M, Mäkinen T, Saharinen P, Immonen I, Alitalo K.

J Clin Invest. 2014 Sep;124(9):3975-86. doi: 10.1172/JCI75395. Epub 2014 Jul 25.

19.

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

Syrjälä SO, Tuuminen R, Nykänen AI, Raissadati A, Dashkevich A, Keränen MA, Arnaudova R, Krebs R, Leow CC, Saharinen P, Alitalo K, Lemström KB.

Am J Transplant. 2014 May;14(5):1096-108. doi: 10.1111/ajt.12672. Epub 2014 Apr 7.

20.

Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

D'Amico G, Korhonen EA, Anisimov A, Zarkada G, Holopainen T, Hägerling R, Kiefer F, Eklund L, Sormunen R, Elamaa H, Brekken RA, Adams RH, Koh GY, Saharinen P, Alitalo K.

J Clin Invest. 2014 Feb;124(2):824-34. doi: 10.1172/JCI68897. Epub 2014 Jan 16.

Supplemental Content

Loading ...
Support Center